Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypertonic saline concentrations delivered by fast nebuliser in cystic fibrosis
ACTRN12610000754044Phase 3Recruiting
- Sponsor
- Royal Prince Alfred Hospital
- Start
- Sep 2010
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hypertonic saline, isotonic saline and quinine in cystic fibrosis (CF) (3 arms), sponsored by Royal Prince Alfred Hospital. Primary endpoint: Change in FEV1 percent predicted at Week 16. Started Sep 2010; status: recruiting.
02
Drugs
hypertonic salineisotonic salinequinine
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ACTRN12610000754044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000754044.